



Subset list of prescription drugs and insulin products for affordability reviews

Table 1 Prescription drug subset list for June 17, 2026, PDAB review

Key: ^Indicates a drug reviewed in 2025

Proprietary name	Non-proprietary name	Therapeutic class	Main conditions treated	Therapeutic alternatives (<i>non-proprietary name</i>)
Jardiance[^]	<i>empagliflozin</i>	Antidiabetics	Treats Type 2 diabetes, heart failure, and chronic kidney disease.	<ul style="list-style-type: none"> - Brenzavvy (<i>bexagliflozin</i>) - Farxiga (<i>dapagliflozin</i>) - Invokana (<i>canagliflozin</i>) - Steglatro (<i>ertugliflozin</i>)
Mounjaro[^]	<i>tirzepatide</i>	Antidiabetics	Improves blood sugar control in adults with type 2 diabetes.	<ul style="list-style-type: none"> - Byetta (<i>exenatide synthetic</i>) - Ozempic (<i>semaglutide</i>) - Rybelsus (<i>semaglutide</i>) - Trulicity (<i>dulaglutide</i>) - Victoza (<i>liraglutide</i>)
Ozempic[^]	<i>semaglutide</i>	Antidiabetics	Improves blood sugar control and lowers the risk of major cardiovascular events in adults with type 2 diabetes.	<ul style="list-style-type: none"> - Byetta (<i>exenatide synthetic</i>) - Mounjaro (<i>trzepatide</i>) - Rybelsus (<i>semaglutide</i>) - Trulicity (<i>dulaglutide</i>) - Victoza (<i>liraglutide</i>)



Table 2 Insulin subset list for June 17, 2026, PDAB review

Proprietary name(s)	Non-proprietary name	Therapeutic class	Insulin subclass	NDC	Main conditions treated
Humulin R U-500 (Concentrated)	<i>Insulin regular</i>	Human insulin	Short acting insulin	00002882427	Improve blood sugar control in adults and children with diabetes (Type-1 and Type 2) who require more than 200 units of insulin per day.
Humulin R U-500 KwikPen	<i>Insulin regular</i>	Human insulin	Short acting insulin	00002850101	Improve blood sugar control in adults and children with diabetes (Type-1 and Type 2) who require more than 200 units of insulin per day.

Table 3 Prescription drug subset list for July 15, 2026, PDAB review

*Indicates a drug with a designated orphan condition

Proprietary name	Non-proprietary name	Therapeutic class	Main conditions treated	Therapeutic alternatives (<i>non-proprietary name</i>)
Keytruda*	<i>pembrolizumab</i>	Antineoplastics and adjunctive therapies	Treats many types of cancers: Skin, lung, blood, bladder, gastrointestinal, gynecologic, and breast. Orphan conditions: Treats rare melanoma, classic Hodgkin Lymphoma; primary mediastinal large B-cell lymphoma; small cell lung cancer.	<ul style="list-style-type: none"> - Bavencio (<i>avelumab</i>) - Jemperli (<i>dostarlimab-gxly</i>) - Imfinzi (<i>durvalumab</i>) - Libtayo (<i>cempilumab-rwlc</i>) - Opdivo (<i>nivolumab</i>) - Tecentriq (<i>atezolizumab</i>)



Proprietary name	Non-proprietary name	Therapeutic class	Main conditions treated	Therapeutic alternatives (<i>non-proprietary name</i>)
Verzenio	<i>abemaciclib</i>	Antineoplastics and adjunctive therapies	Treatment of hormone receptor–positive (HR+), HER2-negative breast cancer in adults across both early-stage and advanced disease.	<ul style="list-style-type: none"> - Ibrance (<i>palbociclib</i>) - Kisqali (<i>ribociclib succinate</i>)
Xeljanz	<i>tofacitinib citrate</i>	Analgesics - anti-inflammatory	Treats several autoimmune and inflammatory conditions in adults and children: Rheumatoid arthritis (RA) – Adults; Psoriatic arthritis (PsA) – Adults; Ankylosing spondylitis (AS) – Adults; Ulcerative colitis (UC) – Adults; Polyarticular Course Juvenile Idiopathic Arthritis (pcJIA) – Pediatric (≥2 years).	Under collection

Table 4 Prescription drug subset list for August 19, 2026, PDAB review

*Indicates a drug with a designated orphan condition

Proprietary name	Non-proprietary name	Therapeutic class	Main conditions treated	Therapeutic alternatives (<i>non-proprietary name</i>)
Ocrevus	<i>ocrelizumab</i>	Immuno-modulatory agent	Treats relapsing forms of multiple sclerosis and primary progressive multiple sclerosis in adults.	<ul style="list-style-type: none"> - Briumvi (<i>ublituximab-xiiy</i>) - Kesimpta (<i>ofatumumab</i>) - Lemtrada (<i>alemtuzumab</i>) - Tysabri (<i>natalizumab</i>)



Proprietary name	Non-proprietary name	Therapeutic class	Main conditions treated	Therapeutic alternatives (<i>non-proprietary name</i>)
Skyrizi*	<i>risankizumab-rzaa</i>	Dermatologicals	Immune-mediated inflammatory conditions: Moderate-to-severe plaque psoriasis; active psoriatic arthritis; moderately to severely active Crohn’s disease; and moderately to severely active ulcerative colitis. Orphan condition: Treatment of pediatric Crohn's disease.	<ul style="list-style-type: none"> - Enbrel (<i>etanercept</i>) - Humira (<i>adalimumab</i>) - Ilumya (<i>tildrakizumab-asmn</i>) - Omvoh (<i>mirikizumab-mrkz</i>) - Remicade (<i>infliximab</i>) - Stelara (<i>ustekinumab</i>) - Taltz (<i>ixekizumab</i>) - Tremfya (<i>guselkumab</i>)
Tremfya	<i>guselkumab</i>	Dermatologicals	Treats immune-mediated inflammatory conditions: moderate-to-severe plaque psoriasis; active psoriatic arthritis; and moderately to severely active ulcerative colitis.	<ul style="list-style-type: none"> - Cosentyx (<i>secukinumab</i>) - Ilumya (<i>tildrakizumab-asmn</i>) - Siliq (<i>brodalumab</i>) - Skyrizi (<i>risankizumab-rzaa</i>) - Stelara (<i>ustekinumab</i>) - Taltz (<i>ixekizumab</i>)
Xolair	<i>omalizumab</i>	Antiasthmatic and bronchodilator agents	Treats allergic and inflammatory conditions in both adults and children: Moderate to severe persistent asthma; chronic rhinosinusitis with nasal polyps (CRSwNP); IgE-mediated food allergy; and chronic spontaneous urticaria (CSU).	<ul style="list-style-type: none"> - Cinqair (<i>reslizumab</i>) - Dupixent (<i>dupilumab</i>) - Fasentra (<i>benralizumab</i>) - Nucala (<i>mepolizumab</i>) - Tezspire (<i>tezepelumab-ekko</i>)

Sept. 16 and Oct. 21: The board will review of all drugs and discuss recommendations for annual report.